이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Hikma Pharmaceuticals 대차 대조표 상태
재무 상태 기준 확인 4/6
Hikma Pharmaceuticals 의 총 주주 지분은 $2.3B 이고 총 부채는 $1.2B, 이는 부채 대 자기자본 비율을 53.2% 로 가져옵니다. 총자산과 총부채는 각각 $4.8B 및 $2.5B 입니다. Hikma Pharmaceuticals 의 EBIT는 $712.0M 이며 이자보상배율은 11 입니다. $260.0M 의 현금 및 단기 투자금을 보유하고 있습니다.
주요 정보
53.2%
부채 비율
US$1.22b
부채
| 이자 보상 비율 | 11x |
| 현금 | US$260.00m |
| 주식 | US$2.30b |
| 총 부채 | US$2.55b |
| 총 자산 | US$4.85b |
최근 재무 상태 업데이트
Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Apr 02
Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Dec 27Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet
Sep 19Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Jun 21Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet
Mar 14Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Sep 27Recent updates
Hikma Pharmaceuticals PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 11Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 36% Below Their Intrinsic Value Estimate
Aug 01Is Hikma Pharmaceuticals PLC (LON:HIK) Trading At A 29% Discount?
Apr 24Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Apr 02Hikma Pharmaceuticals PLC's (LON:HIK) Share Price Matching Investor Opinion
Feb 25Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Dec 27An Intrinsic Calculation For Hikma Pharmaceuticals PLC (LON:HIK) Suggests It's 43% Undervalued
Dec 12Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet
Sep 19Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)
Sep 01Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Jun 21Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 28% Above Its Share Price
Jun 02Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet
Mar 14Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)
Feb 21Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Sep 27Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 19% Below Its Share Price
Jun 24These 4 Measures Indicate That Hikma Pharmaceuticals (LON:HIK) Is Using Debt Reasonably Well
Jun 06Here's Why Hikma Pharmaceuticals (LON:HIK) Can Manage Its Debt Responsibly
Feb 26Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 92% Above Its Share Price
Dec 01Is Hikma Pharmaceuticals (LON:HIK) Using Too Much Debt?
Nov 11Is There An Opportunity With Hikma Pharmaceuticals PLC's (LON:HIK) 32% Undervaluation?
Sep 02Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Aug 09Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 26% Below Their Intrinsic Value Estimate
May 21Hikma Pharmaceuticals (LON:HIK) Seems To Use Debt Quite Sensibly
May 03It's Unlikely That Hikma Pharmaceuticals PLC's (LON:HIK) CEO Will See A Huge Pay Rise This Year
Apr 16How Does Hikma Pharmaceuticals PLC (LON:HIK) Stand Up To These Simple Dividend Safety Checks?
Apr 13Hikma Pharmaceuticals PLC (LON:HIK) Looks Interesting, And It's About To Pay A Dividend
Mar 14Hikma Pharmaceuticals PLC Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Feb 28재무 상태 분석
단기부채: HIK 의 단기 자산 ( $2.3B )이 단기 부채( $1.4B ).
장기 부채: HIK 의 단기 자산( $2.3B )이 장기 부채( $1.2B ).
부채 대 자본 내역 및 분석
부채 수준: HIK 의 순부채 대 자기자본 비율( 40.6% )은 높음으로 간주됩니다.
부채 감소: HIK 의 부채 대 자기자본 비율은 지난 5년간 34.1% 에서 53.2% 로 증가했습니다.
부채 범위: HIK 의 부채는 영업 현금 흐름 ( 47.8% )에 의해 잘 충당되었습니다.
이자 보장: HIK 의 부채에 대한 이자 지급은 EBIT( 9.4 x 적용 범위)로 잘 충당됩니다.